Market: median 1d +0.0% · breadth 25.5% advancing across 188 names
Data as of — announcements 2026-07-15 · flow 2026-07-10 · prices 2026-07-14
New today: DTR, EMV, NPM, NXM, SHN, SPL. New names versus yesterday's letter, so a continuing story doesn't read as fresh news.
Read these (6)
Today's announcements worth minutes, not seconds — triaged by deterministic rules (a raise, a result into live flow, quantified materiality). The LLM annotates; it never picks the bucket.
DTR — Widespread REE Mineralisation at Music Valley
DTR's first-pass rock-chip sampling at Music Valley confirms widespread REE mineralisation across three targets with a bonanza-grade outlier (7.13% TREO) and coherent magnet-REE zonation, de-risking the project sufficiently to justify systematic follow-up drilling and infill sampling. The 100% sample success rate and radiometric correlation suggest a legitimate district-scale system rather than isolated pockets.
Materiality: Early-stage exploration success on newly acquired California project; insufficient data on resource size or confidence interval to quantify against $630m market cap, but validates the acquisition thesis and reduces exploration risk substantially.
Priced in? Stock +28% over 5d and +7% over 20d into announcement; modest but material run-up suggests market was already anticipating positive surface results post-acquisition.
EMVision has passed pivotal stroke-detection trial recruitment milestones with no device-related adverse events, and is preparing to expand the emu™ validation to include acute ischaemia detection via FDA pre-submission—a material clinical and commercial expansion from launch. Strong non-dilutive funding position ($17.1m cash + $4.6m remaining grants) supports runway through anticipated FDA De Novo submission in CY26/early CY27.
💰Cash reserves (30 Jun 2026): $17.1m · Non-dilutive funding remaining: $4.6m · Grant funding received (Q): $2.0m · Pivotal Trial status: Past key enrolment milestones; full enrolment expected late CY26/early CY27
Materiality: $2.0m grant funding received represents ~1.4% of market cap; $17.1m cash reserves provide ~5+ quarters of operational runway at typical biotech burn rates; protocol amendment to add ischaemia endpoint is operationally incremental but clinically significant for post-launch differentiation.
Priced in? Stock flat to slightly negative over 20d and 5d (-1% and -2% respectively), suggesting no material run-up into a routine quarterly activity report; clinical progress (recruitment milestones, RFDS feasibility completion, ischaemia expansion preparation) is substantive but typical for a pivotal-stage trial company.
NPM · $6M — Successful placement to advance Las Openas Gold Project
NPM raised A$3.5m at a 23.5% discount to fund completion of the Las Opeñas drill program and resource estimation, following a discovery hole indicating a large-scale Au/Zn/Ag system. The placement was heavily oversubscribed, signalling investor confidence in the project, though stock has retreated 11% over 5d after a 31% run-up.
💰Capital raised: A$3.5m · Issue price: A$0.013 per share · Discount to last trade: 23.5% · Shares issued: ~269m shares
Materiality: Raise equals ~58% of current market cap; proceeds expected to advance near-term exploration targets and resource definition, material for a pre-resource-stage junior.
Priced in? Stock rallied 31% over 20d pre-announcement but has fallen 11% over 5d, suggesting initial enthusiasm has moderated; the discount and oversubscription indicate institutional appetite may not have been fully telegraphed.
🏔 ~250km near SVL.AX ($300M — 53.54× subject cap) · ~300km near ARD.AX ($37M — 6.68× subject cap)
high-confidence read, materiality quantified
NXM — Further Hi-Grade Results at Payns Prospect up to 34.77g/t Au
Payns delivers bonanza-grade intercepts (34.77 g/t Au) within broader shallow, consistent mineralisation, positioning the prospect for maiden resource estimate integration into an updated Wallbrook multi-prospect MRE by Q3 2026. Company has de-risked exploration with completion of 21,985m program; three more prospect assay tranches pending through August.
💰Best intercept: 1m at 34.77 g/t Au · Within wider zone: 5m at 12.83 g/t Au (grade well above bonanza threshold) · Total Payns drilling: 79 RC holes, 6,040m completed · Program scope: 196 holes, 21,985m across 4 prospects at Wallbrook
Materiality: Drilling completion & high-grade intercepts reduce exploration risk on $27m market cap asset ahead of MRE; no quantified resource impact yet—materiality hinges on September MRE size relative to current 304koz Au at Crusader-Templar.
Priced in? Stock down 20% over 20 days and 5% over 5 days pre-announcement; result appears new information, though continued run-up unlikely without MRE or substantial resource upgrade.
SHN upgraded Liontown's gold-focused resource by 13% contained gold and 28% in tonnes, with 75% now in Measured/Indicated classification and 92.3% metallurgical recovery demonstrating near-term milling viability via acquired Mt Moss facility (target mid-2027 start). Updated Mining Study due August 2026 will integrate these results and owner-operator upside.
💰Liontown Gold Study Resource: 1.02Mt @ 3.75g/t Au & 29.9g/t Ag · Contained Au: 122.6 Koz · Contained Ag: 975 Koz · Total Liontown Resource: 7.27Mt @ 3.19g/t AuEq for 745 Koz AuEq
Materiality: Resource upgrade (~122.6 Koz Au in focused gold domain) is material to a $101m market cap company entering production phase; grades are decent (3.75g/t) and recovery rates strong, reducing execution risk for feasibility.
Priced in? Stock down 7% over 20d and 3% over 5d into announcement; no apparent run-up, suggesting modest market pricing of upgrade news.
↘️ PULLBACK · RSI 50 · 5d -3.5%confidence: high
high-confidence read, materiality quantified
SPL — Fully Underwritten Entitlement Offer to Raise $32 Million
3 related announcements
Entitlement Offer Investor Presentation
Quarterly Activities Report and Appendix 4C
SPL is raising $32m (10% of market cap) via fully underwritten entitlement to extend cash runway into FY28 and fund DEP® HER2-Lu Phase 1 and novel dendrimer oncology pipeline expansion, building on recent radioligand therapy preclinical data.
💰Gross proceeds: $32 million · Offer price: $0.57/share · Discount to last close: 25% · Pro forma cash (30 Jun 2026): $44.5 million
Materiality: Raise = ~10% of $318m market cap; pro forma cash $44.5m supports progression into FY28 (duration not specified, insufficient runway quantification).
Priced in? Stock +9% over 20d and +6% over 5d ahead of announce; 25% discount to last close and 22% to TERP suggests market had anticipated capital raise need, though timing/quantum confirmation may cap further upside.
🚀 EXTENDED · RSI 70 · 5d +5.6%confidence: high
high-confidence read, materiality quantified
Also worth a skim (7)
Price-sensitive but routine — quarterlies and updates worth a headline-level pass.
Who bought and sold, by broker cohort, on a T+3 lag — spikes vs each stock's own baseline, multi-session streaks, and warnings where 'buying' is likely someone absorbing an exit.